Alexander Schramm

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1278734/publications.pdf

Version: 2024-02-01

136	7,750	57758	56724
papers	citations	44 h-index	83 g-index

144	144	144	10877
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature, 2015, 526, 700-704.	27.8	478
2	Lysine-Specific Demethylase 1 Is Strongly Expressed in Poorly Differentiated Neuroblastoma: Implications for Therapy. Cancer Research, 2009, 69, 2065-2071.	0.9	405
3	LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nature Genetics, 2012, 44, 1199-1206.	21.4	336
4	The miR-17-92 MicroRNA Cluster Regulates Multiple Components of the TGF-Î² Pathway in Neuroblastoma. Molecular Cell, 2010, 40, 762-773.	9.7	279
5	Mutational dynamics between primary and relapse neuroblastomas. Nature Genetics, 2015, 47, 872-877.	21.4	253
6	MYCN regulates oncogenic MicroRNAs in neuroblastoma. International Journal of Cancer, 2008, 122, 699-704.	5.1	251
7	Meta-analysis of Neuroblastomas Reveals a Skewed ALK Mutation Spectrum in Tumors with MYCN Amplification. Clinical Cancer Research, 2010, 16, 4353-4362.	7.0	243
8	A mechanistic classification of clinical phenotypes in neuroblastoma. Science, 2018, 362, 1165-1170.	12.6	213
9	Deep sequencing reveals differential expression of microRNAs in favorable versus unfavorable neuroblastoma. Nucleic Acids Research, 2010, 38, 5919-5928.	14.5	183
10	Lysine-specific demethylase 1 restricts hematopoietic progenitor proliferation and is essential for terminal differentiation. Leukemia, 2012, 26, 2039-2051.	7.2	171
11	Targeted Expression of Mutated ALK Induces Neuroblastoma in Transgenic Mice. Science Translational Medicine, 2012, 4, 141ra91.	12.4	147
12	Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition. Clinical Cancer Research, 2016, 22, 2470-2481.	7.0	147
13	An integrative genomics screen uncovers ncRNA T-UCR functions in neuroblastoma tumours. Oncogene, 2010, 29, 3583-3592.	5.9	141
14	Human fetal neuroblast and neuroblastoma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes. Genome Biology, 2006, 7, R84.	9.6	134
15	Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors. Gastroenterology, 1996, 110, 1215-1224.	1.3	122
16	BET bromodomain protein inhibition is a therapeutic option for medulloblastoma. Oncotarget, 2013, 4, 2080-2095.	1.8	122
17	Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling. Oncogene, 2005, 24, 7902-7912.	5.9	113
18	The Phox2B homeobox gene is mutated in sporadic neuroblastomas. Oncogene, 2004, 23, 9280-9288.	5.9	112

#	Article	IF	Citations
19	MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors. Oncogene, 2010, 29, 1394-1404.	5.9	112
20	A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies. Oncogene, 2015, 34, 3357-3368.	5.9	112
21	Identification of a Set of Seven Genes for the Monitoring of Minimal Residual Disease in Pediatric Acute Myeloid Leukemia. Clinical Cancer Research, 2006, 12, 2434-2441.	7.0	111
22	Gains and overexpression identify DEK and E2F3 as targets of chromosome 6p gains in retinoblastoma. Oncogene, 2005, 24, 6441-6449.	5.9	108
23	Biological effects of TrkA and TrkB receptor signaling in neuroblastoma. Cancer Letters, 2005, 228, 143-153.	7.2	106
24	High ALK Receptor Tyrosine Kinase Expression Supersedes ALK Mutation as a Determining Factor of an Unfavorable Phenotype in Primary Neuroblastoma. Clinical Cancer Research, 2011, 17, 5082-5092.	7.0	95
25	miRNA Expression Profiling Enables Risk Stratification in Archived and Fresh Neuroblastoma Tumor Samples. Clinical Cancer Research, 2011, 17, 7684-7692.	7.0	92
26	MiRâ€137 functions as a tumor suppressor in neuroblastoma by downregulating KDM1A. International Journal of Cancer, 2013, 133, 1064-1073.	5.1	91
27	IL-2â^'driven Regulation of NK Cell Receptors With Regard to the Distribution of CD16+ and CD16â^' Subpopulations and In Vivo Influence After Haploidentical NK Cell Infusion. Journal of Immunotherapy, 2010, 33, 200-210.	2.4	89
28	Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression. OncoImmunology, 2017, 6, e1320626.	4.6	89
29	Accurate prediction of neuroblastoma outcome based on miRNA expression profiles. International Journal of Cancer, 2010, 127, 2374-2385.	5.1	88
30	Accurate Outcome Prediction in Neuroblastoma across Independent Data Sets Using a Multigene Signature. Clinical Cancer Research, 2010, 16, 1532-1541.	7.0	86
31	MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells. Oncogene, 2013, 32, 1059-1065.	5.9	84
32	Modulation of neuroblastoma disease pathogenesis by an extensive network of epigenetically regulated microRNAs. Oncogene, 2013, 32, 2927-2936.	5.9	84
33	Synthetic lethality between Rb, p53 and Dicer or miR-17â€“92 in retinal progenitors suppresses retinoblastoma formation. Nature Cell Biology, 2012, 14, 958-965.	10.3	79
34	miRâ€542â€3p exerts tumor suppressive functions in neuroblastoma by downregulating <scp>S</scp>urvivin. International Journal of Cancer, 2015, 136, 1308-1320.	5.1	78
35	Microarray analysis reveals differential gene expression patterns and regulation of single target genes contributing to the opposing phenotype of TrkA- and TrkB-expressing neuroblastomas. Oncogene, 2005, 24, 165-177.	5.9	76
36	Chromosomal and MicroRNA Expression Patterns Reveal Biologically Distinct Subgroups of 11qâ^' Neuroblastoma. Clinical Cancer Research, 2010, 16, 2971-2978.	7.0	70

#	Article	IF	Citations
37	ArrayCGHâ€based classification of neuroblastoma into genomic subgroups. Genes Chromosomes and Cancer, 2007, 46, 1098-1108.	2.8	67
38	Polo-Like Kinase 1 is a Therapeutic Target in High-Risk Neuroblastoma. Clinical Cancer Research, 2011, 17, 731-741.	7.0	67
39	Pyruvate Kinase of the Hyperthermophilic Crenarchaeote Thermoproteus tenax : Physiological Role and Phylogenetic Aspects. Journal of Bacteriology, 2000, 182, 2001-2009.	2.2	66
40	Targeting the Phosphoinositide 3-Kinase Isoform p110Î´ Impairs Growth and Survival in Neuroblastoma Cells. Clinical Cancer Research, 2008, 14, 1172-1181.	7.0	63
41	Fractalkine (CX3CL1)â€“ and Interleukin-2â€“Enriched Neuroblastoma Microenvironment Induces Eradication of Metastases Mediated by T Cells and Natural Killer Cells. Cancer Research, 2007, 67, 2331-2338.	0.9	62
42	Galectin-1 is a major effector of TrkB-mediated neuroblastoma aggressiveness. Oncogene, 2009, 28, 2015-2023.	5.9	61
43	Hypoxia Induces Resistance to EGFR Inhibitors in Lung Cancer Cells via Upregulation of FGFR1 and the MAPK Pathway. Cancer Research, 2020, 80, 4655-4667.	0.9	52
44	Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas. Neuro-Oncology, 2012, 14, 859-869.	1.2	48
45	Dickkopfâ€3 is regulated by the MYCNâ€induced miRâ€17â€92 cluster in neuroblastoma. International Journal of Cancer, 2012, 130, 2591-2598.	5.1	43
46	Meta-mining of Neuroblastoma and Neuroblast Gene Expression Profiles Reveals Candidate Therapeutic Compounds. Clinical Cancer Research, 2009, 15, 3690-3696.	7.0	41
47	Smac Mimetic LBW242 Sensitizes XIAP-Overexpressing Neuroblastoma Cells for TNF-Î±â€“Independent Apoptosis. Cancer Research, 2012, 72, 2645-2656.	0.9	41
48	<scp>M</scp>i<scp>R</scp>â€34a deficiency accelerates medulloblastoma formation in vivo. International Journal of Cancer, 2015, 136, 2293-2303.	5.1	40
49	Regulatory BCL2 promoter polymorphism (â^'938C>A) is associated with adverse outcome in patients with prostate carcinoma. International Journal of Cancer, 2011, 129, 2390-2399.	5.1	39
50	MicroRNAs in the pathogenesis of neuroblastoma. Cancer Letters, 2009, 274, 10-15.	7.2	37
51	Identification of a novel recurrent 1q42.2â€1qter deletion in high risk MYCN single copy 11q deleted neuroblastomas. International Journal of Cancer, 2012, 130, 2599-2606.	5.1	37
52	Focal DNA Copy Number Changes in Neuroblastoma Target MYCN Regulated Genes. PLoS ONE, 2013, 8, e52321.	2.5	37
53	Sensitivity to cdk1-inhibition is modulated by p53 status in preclinical models of embryonal tumors. Oncotarget, 2015, 6, 15425-15435.	1.8	37
54	Identification of Dynamic Proteome Changes Upon Ligand Activation of Trk-Receptors Using Two-dimensional Fluorescence Difference Gel Electrophoresis and Mass Spectrometry. Molecular and Cellular Proteomics, 2005, 4, 291-299.	3.8	36

#	Article	IF	Citations
55	Keratoepithelin Suppresses the Progression of Experimental Human Neuroblastomas. Cancer Research, 2006, 66, 5314-5321.	0.9	36
56	CADM1 is a strong neuroblastoma candidate gene that maps within a 3.72 Mb critical region of loss on 11q23. BMC Cancer, 2008, 8, 173.	2.6	34
57	Neuroblastoma tumorigenesis is regulated through the Nm23-H1/h-Prune C-terminal interaction. Scientific Reports, 2013, 3, 1351.	3.3	34
58	The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models. Oncotarget, 2017, 8, 6730-6741.	1.8	34
59	High activin A-expression in human neuroblastoma: suppression of malignant potential and correlation with favourable clinical outcome. Oncogene, 2005, 24, 680-687.	5.9	33
60	Structure and Function of a Regulated Archaeal Triosephosphate Isomerase Adapted to High Temperature. Journal of Molecular Biology, 2004, 342, 861-875.	4.2	32
61	Overcoming drug resistance by cell-penetrating peptide-mediated delivery of a doxorubicin dimer with high DNA-binding affinity. European Journal of Medicinal Chemistry, 2017, 130, 336-345.	5.5	31
62	Homozygous loss of the MTSl/pl6 and MTS2/pl5 genes in lymphoma and lymphoblastic leukaemia cell lines. British Journal of Haematology, 1995, 91, 350-354.	2.5	30
63	Expression analysis of pediatric solid tumor cell lines using oligonucleotide microarrays. International Journal of Oncology, 2002, 20, 441.	3.3	30
64	The metallophosphodiesterase Mpped2 impairs tumorigenesis in neuroblastoma. Cell Cycle, 2012, 11, 569-581.	2.6	30
65	Transcription factor AP2alpha (TFAP2a) regulates differentiation and proliferation of neuroblastoma cells. Cancer Letters, 2008, 271, 56-63.	7.2	29
66	Targeted Therapy for Neuroblastoma: ALK Inhibitors. Klinische Padiatrie, 2013, 225, 303-308.	0.6	29
67	Translating Expression Profiling into a Clinically Feasible Test to Predict Neuroblastoma Outcome. Clinical Cancer Research, 2007, 13, 1459-1465.	7.0	28
68	Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project. Expert Opinion on Drug Discovery, 2017, 12, 1-11.	5.0	28
69	Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients. JCI Insight, 2018, 3, .	5.0	28
70	Phox2B mutations and the Deltaâ€“Notch pathway in neuroblastoma. Cancer Letters, 2005, 228, 59-63.	7.2	27
71	Bone morphogenetic protein-7 is a MYC target with prosurvival functions in childhood medulloblastoma. Oncogene, 2011, 30, 2823-2835.	5.9	27
72	The KDM1A histone demethylase is a promising new target for the epigenetic therapy of medulloblastoma. Acta Neuropathologica Communications, 2013, 1, 19.	5.2	26

#	Article	IF	Citations
73	Nextâ€generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCNâ€amplified neuroblastoma. International Journal of Cancer, 2013, 132, E106-15.	5.1	26
74	Neuroblastoma in dialog with its stroma: NTRK1 is a regulator of cellular cross-talk with Schwann cells. Oncotarget, 2014, 5, 11180-11192.	1.8	26
75	Absence of telomerase reverse transcriptase promoter mutations in neuroblastoma. Biomedical Reports, 2015, 3, 443-446.	2.0	25
76	Exon-level expression analyses identify MYCN and NTRK1 as major determinants of alternative exon usage and robustly predict primary neuroblastoma outcome. British Journal of Cancer, 2012, 107, 1409-1417.	6.4	24
77	Functional screening identifies aryl hydrocarbon receptor as suppressor of lung cancer metastasis. Oncogenesis, 2020, 9, 102.	4.9	24
78	Plasma Next Generation Sequencing and Droplet Digital-qPCR-Based Quantification of Circulating Cell-Free RNA for Noninvasive Early Detection of Cancer. Cancers, 2020, 12, 353.	3.7	24
79	Statins affect cancer cell plasticity with distinct consequences for tumor progression and metastasis. Cell Reports, 2021, 37, 110056.	6.4	24
80	Xenogeneic immunization with human tyrosine hydroxylase DNA vaccines suppresses growth of established neuroblastoma. Molecular Cancer Therapeutics, 2009, 8, 2392-2401.	4.1	23
81	Application of the PAMONO-Sensor for Quantiï¬cation of Microvesicles and Determination of Nano-Particle Size Distribution. Sensors, 2017, 17, 244.	3.8	23
82	HER2 mediates clinical resistance to the KRASG12C inhibitor sotorasib, which is overcome by co-targeting SHP2. European Journal of Cancer, 2021, 159, 16-23.	2.8	23
83	Identification of 2 putative critical segments of 17q gain in neuroblastoma through integrative genomics. International Journal of Cancer, 2008, 122, 1177-1182.	5.1	22
84	Evolution of melanoma cross-resistance to CD8+ T cells and MAPK inhibition in the course of BRAFi treatment. OncoImmunology, 2018, 7, e1450127.	4.6	22
85	Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma. Cancer Letters, 2019, 445, 24-33.	7.2	22
86	Cancer evolution, mutations, and clonal selection in relapse neuroblastoma. Cell and Tissue Research, 2018, 372, 263-268.	2.9	21
87	Characterization of pancreatic glucagon-producing tumors and pituitary gland tumors in transgenic mice overexpressingMYCNinhGFAP-positive cells. Oncotarget, 2016, 7, 74415-74426.	1.8	21
88	High resolution tiling-path BAC array deletion mapping suggests commonly involved 3p21-p22 tumor suppressor genes in neuroblastoma and more frequent tumors. International Journal of Cancer, 2007, 120, 533-538.	5.1	20
89	Expression of NTRK1/TrkA affects immunogenicity of neuroblastoma cells. International Journal of Cancer, 2013, 133, 908-919.	5.1	20
90	Taraxacum officinale extract shows antitumor effects on pediatric cancer cells and enhance mistletoe therapy. Complementary Therapies in Medicine, 2018, 40, 158-164.	2.7	20

#	Article	IF	Citations
91	Tumor-Derived Extracellular Vesicles Impair CD171-Specific CD4+ CAR T Cell Efficacy. Frontiers in Immunology, 2020, 11, 531.	4.8	20
92	Characterization and chromosomal assignment of yeast artificial chromosomes containing human 3p13-p21-specific sequence tagged sites. Cancer Genetics and Cytogenetics, 1995, 81, 1-12.	1.0	19
93	N-Myc-induced metabolic rewiring creates novel therapeutic vulnerabilities in neuroblastoma. Scientific Reports, 2020, 10, 7157.	3.3	19
94	Druggable epigenetic suppression of interferon-induced chemokine expression linked to MYCN amplification in neuroblastoma. , 2021, 9, e001335.		19
95	Targeting tachykinin receptors in neuroblastoma. Oncotarget, 2017, 8, 430-443.	1.8	19
96	Expression of the TrkA or TrkB receptor tyrosine kinase alters the double-strand break (DSB) repair capacity of SY5Y neuroblastoma cells. DNA Repair, 2008, 7, 1757-1764.	2.8	18
97	Immune response modulation by Galectin-1 in a transgenic model of neuroblastoma. OncoImmunology, 2016, 5, e1131378.	4.6	18
98	Targeting of MYCN by means of DNA vaccination is effective against neuroblastoma in mice. Cancer Immunology, Immunotherapy, 2015, 64, 1215-1227.	4.2	17
99	The lowâ€affinity neurotrophin receptor, p75, is upregulated in ganglioneuroblastoma/ganglioneuroma and reduces tumorigenicity of neuroblastoma cells in vivo. International Journal of Cancer, 2009, 124, 2488-2494.	5.1	15
100	Design of a multi-signature ensemble classifier predicting neuroblastoma patients' outcome. BMC Bioinformatics, 2012, 13, S13.	2.6	15
101	Proteomics: Techniques and Applications in Cancer Research. Klinische Padiatrie, 2003, 215, 293-297.	0.6	13
102	Application of microarray-based technology to neuroblastoma. Cancer Letters, 2005, 228, 13-20.	7.2	13
103	Design of a Modular Protein-Based MRI Contrast Agent for Targeted Application. PLoS ONE, 2013, 8, e65346.	2.5	13
104	Microarray-Analysis: A New Approach to Study the Molecular Mechanisms of Thermo-Chemotherapy. Klinische Padiatrie, 2003, 215, 298-302.	0.6	12
105	Design, synthesis and biological evaluation of Î²-peptoid-capped HDAC inhibitors with anti-neuroblastoma and anti-glioblastoma activity. MedChemComm, 2019, 10, 1109-1115.	3.4	11
106	Reanalysis of neuroblastoma expression profiling data using improved methodology and extended follow-up increases validity of outcome prediction. Cancer Letters, 2009, 282, 55-62.	7.2	10
107	Identifying transcriptional miRNA biomarkers by integrating high-throughput sequencing and real-time PCR data. Methods, 2013, 59, 154-163.	3.8	10
108	[6] Triose-phosphate isomerase from Pyrococcus woesei and Methanothermus fervidus. Methods in Enzymology, 2001, 331, 62-77.	1.0	9

#	Article	IF	Citations
109	Keratoepithelin reverts the suppression of tissue factor pathway inhibitor 2 by MYCN in human neuroblastoma: A mechanism to inhibit invasion. International Journal of Oncology, 2008, , .	3.3	9
110	HDAC inhibition synergizes with ALK inhibitors to overcome resistance in a novel ALK mutated lung adenocarcinoma model. Lung Cancer, 2020, 144, 20-29.	2.0	9
111	The BCL2-938 Câ€‰›â€‰A promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia. BMC Cancer, 2013, 13, 452.	2.6	8
112	Pharmaceutically inhibiting poloâ€like kinase 1 exerts a broad antiâ€tumour activity in retinoblastoma cell lines. Clinical and Experimental Ophthalmology, 2017, 45, 288-296.	2.6	8
113	Preclinical Evaluation of Antitumoral and Cytotoxic Properties of Viscum album Fraxini Extract on Pediatric Tumor Cells. Planta Medica, 2019, 85, 1150-1159.	1.3	8
114	The mitochondrial genetic landscape in neuroblastoma from tumor initiation to relapse. Oncotarget, 2016, 7, 6620-6625.	1.8	8
115	Anticancer Effects of <i>Viscum album</i> Fraxini Extract on Medulloblastoma Cells in vitro. Complementary Medicine Research, 2021, 28, 15-22.	1.2	7
116	NTRK1/TrkA Signaling in Neuroblastoma Cells Induces Nuclear Reorganization and Intra-Nuclear Aggregation of Lamin A/C. Cancers, 2021, 13, 5293.	3.7	7
117	Combined multimodal ctDNA analysis and radiological imaging for tumor surveillance in Non-small cell lung cancer. Translational Oncology, 2022, 15, 101279.	3.7	7
118	TrkB-Target Galectin-1 Impairs Immune Activation and Radiation Responses in Neuroblastoma: Implications for Tumour Therapy. International Journal of Molecular Sciences, 2018, 19, 718.	4.1	6
119	Robust Selection of Cancer Survival Signatures from High-Throughput Genomic Data Using Two-Fold Subsampling. PLoS ONE, 2014, 9, e108818.	2.5	6
120	The mutational landscape of MYCN, Lin28b and ALKF1174L driven murine neuroblastoma mimics human disease. Oncotarget, 2018, 9, 8334-8349.	1.8	6
121	Abstract LB-210: Telomerase activation by genomic rearrangements in high-risk neuroblastoma. , 2015, , .		5
122	Identification and Tumour-Binding Properties of a Peptide with High Affinity to the Disialoganglioside GD2. PLoS ONE, 2016, 11, e0163648.	2.5	5
123	MYCN-targeting vaccines and immunotherapeutics. Human Vaccines and Immunotherapeutics, 2016, 12, 2257-2258.	3.3	4
124	RITA displays anti-tumor activity in medulloblastomas independent of TP53 status. Oncotarget, 2017, 8, 27882-27891.	1.8	4
125	The clinical utility of <scp>cfRNA</scp> for disease detection and surveillance: A proof of concept study in nonâ€small cell lung cancer. Thoracic Cancer, 2022, 13, 2180-2191.	1.9	4
126	Discovery of a New Bioactive Molecule for Neuroblastoma. Chemical Biology and Drug Design, 2013, 82, 233-241.	3.2	3

#	Article	IF	Citations
127	MYCN-mediated murine cancer models. Aging, 2017, 9, 1084-1085.	3.1	3
128	EIF4EBP1 is transcriptionally upregulated by MYCN and associates with poor prognosis in neuroblastoma. Cell Death Discovery, 2022, 8, 157.	4.7	3
129	Towards diagnostic application of non-coding RNAs in neuroblastoma. Expert Review of Molecular Diagnostics, 2016, 16, 1307-1313.	3.1	2
130	NTRK1/TrkA Activation Overrides the G2/M-Checkpoint upon Irradiation. Cancers, 2021, 13, 6023.	3.7	2
131	Streamlining Quantitative Analysis of Long RNA Sequencing Reads. International Journal of Molecular Sciences, 2020, 21, 7259.	4.1	1
132	Syntaxin 18 regulates the DNA damage response and epithelial-to-mesenchymal transition to promote radiation resistance of lung cancer. Cell Death and Disease, 2022, 13, .	6.3	1
133	Abstract 1683: ALK F1174L kinase activity as driver of cell proliferation in neuroblastoma cell line models and neuroblastoma tumors. , 2012, , .		0
134	Abstract 4596: LIN28B drives neuroblastoma oncogenesis through let7-MYCN signaling.. , 2013, , .		0
135	Abstract 3967: BET protein inhibitor OTX015 has selective anti-tumoral activity in preclinical models of MYCN- amplified neuroblastoma. , 2014, , .		0
136	Abstract 4731: Targeting super-enhancer induced gene expression with the novel BRD4 inhibitor OTX015 in preclinical models of MYCN-amplified neuroblastoma. , 2015, , .		0